EXEL

SEC source: 0000939767-21-000049 · wf-form4_162095233683684.xml · nonDerivative · entry 3

PAPADOPOULOS STELIOS · CIK 0001202098 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,258,675

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-21-000049 · wf-form4_162095233683684.xml · nonDerivative · entry 2

PAPADOPOULOS STELIOS · CIK 0001202098 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,218,675

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.93 to $24.97. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

SEC source: 0000939767-21-000049 · wf-form4_162095233683684.xml · nonDerivative · entry 1

PAPADOPOULOS STELIOS · CIK 0001202098 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,228,897

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 15,538 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000054 · wf-form4_162129692660785.xml · nonDerivative · entry 1

Freire Maria C · CIK 0001547999 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,827

F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.95 to $25.08. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4.

F2 · balance_after: Includes 11,258 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000051 · wf-form4_162103985398361.xml · nonDerivative · entry 1

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 1,019,067

F1 · kind: Represents shares of Exelixis, Inc. common stock ("Common Stock") that the Reporting Person donated as a gift to a donor advised fund.

F2 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended.

SEC source: 0000939767-21-000043 · wf-form4_161965500597259.xml · derivative · entry 4

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2021-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.

SEC source: 0000939767-21-000043 · wf-form4_161965500597259.xml · nonDerivative · entry 2

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 613,482

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2021.

SEC source: 0000939767-21-000043 · wf-form4_161965500597259.xml · nonDerivative · entry 1

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 663,482

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000042 · wf-form4_161965486730408.xml · nonDerivative · entry 1

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 297,392

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2021.

F2 · balance_after: Includes 230,390 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000041 · wf-form4_161965479571792.xml · nonDerivative · entry 1

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 628,248

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2020.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.08. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

F3 · balance_after: Includes 193,455 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000040 · wf-form4_161740743547342.xml · derivative · entry 4

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2021-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 400,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.

SEC source: 0000939767-21-000040 · wf-form4_161740743547342.xml · nonDerivative · entry 2

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 389,467

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2020.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.58 to $23.14. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-21-000040 · wf-form4_161740743547342.xml · nonDerivative · entry 1

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 449,467

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 215,102 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000039 · wf-form4_161740683370551.xml · derivative · entry 4

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2021-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.

SEC source: 0000939767-21-000039 · wf-form4_161740683370551.xml · nonDerivative · entry 2

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 613,482

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2021.

SEC source: 0000939767-21-000039 · wf-form4_161740683370551.xml · nonDerivative · entry 1

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 663,482

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000038 · wf-form4_161723893234049.xml · derivative · entry 3

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2021-05-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 29, 2014.

SEC source: 0000939767-21-000038 · wf-form4_161723893234049.xml · nonDerivative · entry 2

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 231,589

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2021.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.03 to $22.91. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-21-000038 · wf-form4_161723893234049.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,809

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 7,728 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000037 · wf-form4_161602625006192.xml · derivative · entry 3

Garber Alan M · CIK 0001312907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2021-05-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 29, 2014.

SEC source: 0000939767-21-000037 · wf-form4_161602625006192.xml · nonDerivative · entry 2

Garber Alan M · CIK 0001312907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,718

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 25, 2020.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.09 to $23.74. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

SEC source: 0000939767-21-000037 · wf-form4_161602625006192.xml · nonDerivative · entry 1

Garber Alan M · CIK 0001312907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,718

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-21-000036 · wf-form4_161499266657333.xml · derivative · entry 4

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 494,700

Underlying: Common Stock · 494,700 shares

Expires 2028-03-03

F5 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date.

SEC source: 0000939767-21-000035 · wf-form4_161499254775903.xml · nonDerivative · entry 1

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 613,482

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2022 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested.

F3 · balance_after: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000033 · wf-form4_161499238918592.xml · nonDerivative · entry 1

Senner Christopher J. · CIK 0001648367 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 356,591

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2022 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested.

F3 · balance_after: Includes 208,343 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000034 · wf-form4_161499247200887.xml · nonDerivative · entry 1

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 646,248

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2022 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested.

F3 · balance_after: Includes 193,455 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000032 · wf-form4_161499230238974.xml · nonDerivative · entry 1

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,057

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2022 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested.

F3 · balance_after: Includes 230,390 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000031 · wf-form4_161499218634349.xml · nonDerivative · entry 1

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 389,467

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2022 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested.

F3 · balance_after: Includes 215,102 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000029 · wf-form4_161481892190996.xml · derivative · entry 4

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 65,000 shares

Expires 2021-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 400,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.

SEC source: 0000939767-21-000029 · wf-form4_161481892190996.xml · nonDerivative · entry 2

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 340,072

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2020.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.65 to $22.45. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-21-000029 · wf-form4_161481892190996.xml · nonDerivative · entry 1

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 405,072

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 165,707 be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000026 · wf-form4_161438823233506.xml · derivative · entry 3

COHEN CHARLES · CIK 0001202089 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2021-05-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 29, 2014.

SEC source: 0000939767-21-000026 · wf-form4_161438823233506.xml · nonDerivative · entry 2

COHEN CHARLES · CIK 0001202089 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,375

F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.57 to $22.84. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4.

SEC source: 0000939767-21-000026 · wf-form4_161438823233506.xml · nonDerivative · entry 1

COHEN CHARLES · CIK 0001202089 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,375

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-21-000036 · wf-form4_161499266657333.xml · nonDerivative · entry 2

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 1,059,683

F1 · kind: On February 24, 2021, the Reporting Person gifted 67,374 shares of Exelixis, Inc. common stock to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended

F3 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended.

SEC source: 0000939767-21-000036 · wf-form4_161499266657333.xml · nonDerivative · entry 1

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 491,813

F1 · kind: On February 24, 2021, the Reporting Person gifted 67,374 shares of Exelixis, Inc. common stock to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended

F2 · balance_after: Includes 491,813 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000023 · wf-form4_161421549385793.xml · derivative · entry 5

WILLSEY LANCE · CIK 0001202106 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2021-05-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 29, 2014.

SEC source: 0000939767-21-000023 · wf-form4_161421549385793.xml · nonDerivative · entry 4

WILLSEY LANCE · CIK 0001202106 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 424,415

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.31 to $22.37. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-21-000023 · wf-form4_161421549385793.xml · nonDerivative · entry 3

WILLSEY LANCE · CIK 0001202106 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 425,215

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.31 to $22.30. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

SEC source: 0000939767-21-000023 · wf-form4_161421549385793.xml · nonDerivative · entry 2

WILLSEY LANCE · CIK 0001202106 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 464,415

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-21-000025 · wf-form4_161421584386456.xml · derivative · entry 2

POSTE GEORGE · CIK 0001180770 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2021-05-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 29, 2014.

SEC source: 0000939767-21-000025 · wf-form4_161421584386456.xml · nonDerivative · entry 1

POSTE GEORGE · CIK 0001180770 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,992

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 15,538 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000024 · wf-form4_161421570407092.xml · nonDerivative · entry 1

MARCHESI VINCENT T · CIK 0001202095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,115

F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.27 to $22.30. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4.

F2 · balance_after: Includes 7,728 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000021 · wf-form4_161378260922150.xml · derivative · entry 7

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 50,000 shares

Expires 2021-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.

SEC source: 0000939767-21-000021 · wf-form4_161378260922150.xml · nonDerivative · entry 4

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 540,597

SEC source: 0000939767-21-000021 · wf-form4_161378260922150.xml · nonDerivative · entry 3

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 590,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-21-000021 · wf-form4_161378260922150.xml · derivative · entry 6

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 50,000 shares

Expires 2021-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.

SEC source: 0000939767-21-000021 · wf-form4_161378260922150.xml · nonDerivative · entry 2

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 540,597

SEC source: 0000939767-21-000021 · wf-form4_161378260922150.xml · nonDerivative · entry 1

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 590,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 171,083 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000014 · wf-form4_161361018341592.xml · derivative · entry 3

FELDBAUM CARL B · CIK 0001326377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2021-05-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 29, 2014.